FOLFIRI (Fluorouracil, Leucovorin, Irinotecan)
Treatment for Colon And Rectum Cancer
Typical Dosage: Irinotecan 180mg/m2, Leucovorin 400mg/m2, Fluorouracil 400mg/m2 bolus then 2400mg/m2 infusion, every 2 weeks
Effectiveness
83%
Safety Score
25%
Clinical Trials
49
Participants
40K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Dosage Range
Irinotecan 180mg/m2, Leucovorin 400mg/m2, Fluorouracil 400mg/m2 bolus then 2400mg/m2 infusion, every 2 weeks
Time to Effect
6-9 weeks
Treatment Duration
Until progression
Evidence Quality
HIGHConfidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$15,000
Monitoring:$15,000
Side Effect Mgmt:$10,000
Total Annual:$40,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$80,000/QALY
QALYs Gained
0.8
Outcome-Based Costs
Cost per Responder
$100,000
Cost per Remission
$800,000
Comparison vs FOLFOX
Cost Difference
$-5,000/year
Less expensive
QALY Difference
-0.10 QALYs
Worse outcomes
Dominance
No dominance
FOLFIRI (Fluorouracil, Leucovorin, Irinotecan) Outcomes
for Colon And Rectum Cancer
Efficacy Outcomes
Overall Effectiveness
+83%
Response Rate
+40%
Remission Rate
+5%
Common Side Effects
Diarrhea
+80%
Myelosuppression
+70%
Fatigue
+80%
Nausea/Vomiting
+60%
Alopecia
+50%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
15 completed trials for FOLFIRI (Fluorouracil, Leucovorin, Irinotecan) in Colon And Rectum Cancer
Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
NCT00967616COMPLETEDPHASE2
100 participants
INTERVENTIONAL
Beverly Hills, United States +17 more
Started: Sep 1, 2009
Phase I Trial of Combination of FOLFIRI and SOM 230
NCT01434069COMPLETEDPHASE1
16 participants
INTERVENTIONAL
Tampa, United States
Started: Sep 1, 2011
Phase 2 Study of DKN-01 in Colorectal Cancer
NCT05480306COMPLETEDPHASE2
188 participants
INTERVENTIONAL
Tucson, United States +39 more
Started: Aug 30, 2022
Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to Treatment
NCT00411450COMPLETEDPHASE2
116 participants
INTERVENTIONAL
Started: Nov 1, 2006
SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial
NCT00418938COMPLETEDPHASE2
266 participants
INTERVENTIONAL
Started: Nov 1, 2006
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
NCT00265850COMPLETEDPHASE3
2.33K participants
INTERVENTIONAL
Mobile, United States +682 more
Started: Nov 1, 2005
Combination Chemotherapy and Bevacizumab With or Without Bevacizumab Maintenance Therapy in Treating Patients With Metastatic Colorectal Cancer
NCT00952029COMPLETEDPHASE2, PHASE3
492 participants
INTERVENTIONAL
Abbeville, France +101 more
Started: Mar 1, 2010
Combination Chemotherapy in Treating Patients With Colorectal Cancer and Resectable Metastases
NCT00268398COMPLETEDPHASE3
284 participants
INTERVENTIONAL
Avignon, France +31 more
Started: Jul 1, 2002
G-CSF in Preventing Neutropenia During First-Line Treatment With Chemotherapy and Bevacizumab in Patients With Metastatic Colorectal Cancer
NCT00541125COMPLETEDPHASE2
20 participants
INTERVENTIONAL
Started: Nov 1, 2007
Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab
NCT01814501COMPLETEDPHASE2
16 participants
INTERVENTIONAL
Columbus, United States +1 more
Started: Feb 1, 2013
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
NCT00911170COMPLETEDPHASE3
847 participants
INTERVENTIONAL
Muscle Shoals, United States +153 more
Started: Nov 3, 2009
A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma
NCT00752570COMPLETEDPHASE2
144 participants
INTERVENTIONAL
Started: Nov 1, 2008
Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung
NCT00557102COMPLETEDPHASE2
24 participants
INTERVENTIONAL
Grenoble, France
Started: Sep 1, 2007
QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
NCT00813605COMPLETEDPHASE2
155 participants
INTERVENTIONAL
Beverly Hills, United States +66 more
Started: Mar 1, 2009
Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer
NCT01383343COMPLETEDPHASE1
17 participants
INTERVENTIONAL
Scottsdale, United States +2 more
Started: Aug 1, 2011
Showing 20 of 49 total trials